Capabilities
King & Spalding’s antitrust lawyers provide sophisticated, solution-oriented advice to clients in a wide variety of industries on all aspects of U.S. and international competition law, including mergers and acquisitions, joint ventures and other strategic alliances, government civil and criminal investigations, private antitrust litigation and counseling. Clients rely on our antitrust lawyers for constructive counseling and guidance on legitimate arrangements between competitors, entry into new markets, product distribution systems and appropriate participation by clients at trade associations and standard-setting organizations, as well as to steer them through complex civil, criminal, and merger investigations and litigation. The key to our antitrust success is consistent, comprehensive and responsive counsel to our clients.
Our antitrust lawyers include several who have served in significant positions within U.S. antitrust enforcement agencies, including the former Deputy Bureau Director of the Federal Trade Commission, former Deputy Assistant Attorney General for Criminal Enforcement at the Antitrust Division of the Department of Justice, and a number of other DOJ and FTC veterans. We regularly appear before these and other key competition authorities, including state attorneys general.
Our lawyers also have substantial experience coordinating efforts to gain approval of transactions from the EU and other non-U.S. antitrust authorities, including guiding clients through Phase II merger investigations, responding to Article 11 letters and advising clients on issues of jurisdiction and disclosure of information from abroad.
Our lawyers are also active in the Antitrust Section of the American Bar Association and the Antitrust Practice Group of the American Health Lawyers Association, where our lawyers hold or have held numerous leadership positions, including Co-Chair of the Mergers and Acquisitions Committee, Chair of the Criminal Practice and Procedure Committee, and Vice-Chair of the Cartel and Criminal Practice Committee.
January 8, 2019
New House Democratic Majority Proposes Aggressive Antitrust Scrutiny
December 12, 2018
Trump Administration Calls for Heightened Scrutiny of Competition in the Healthcare Industry
December 7, 2018
FTC Comment on FDA Guidance
February 8, 2019
John Carroll discusses the top healthcare antitrust developments of 2018 and what to look for in 2019
January 4, 2019
Chris Yook comments on the FTC's review of the NxStage/Fresenius deal likely focusing on IP licensing related to the Medisystems divestiture
January 29, 2018
King & Spalding Advises WestRock on Antitrust Aspects of $4.9 Billion Acquisition of KapStone
December 20, 2017
LCCG Turns to King & Spalding on €230 Million Acquisition of GPE